Meeting Overview - The second board meeting of Jianerkang Medical Technology Co., Ltd. was held on August 28, 2025, with all 9 directors present, complying with relevant laws and regulations [1][2]. Resolutions Passed - The board approved the full and summary reports for the 2025 semi-annual report, with a unanimous vote of 9 in favor [2]. - The board also approved the special report on the storage and use of raised funds for the first half of 2025, again with a unanimous vote of 9 in favor [2]. - A resolution was passed to change the company's registered capital, abolish the supervisory board, and amend the company's articles of association, with a unanimous vote of 9 in favor. This change aligns with the new Company Law effective from July 1, 2024 [3][4]. - The board approved the revision and formulation of several governance systems to enhance operational standards and governance structure, with a unanimous vote of 9 in favor [4]. - A proposal to convene the first extraordinary general meeting of shareholders in 2025 was also approved, with a unanimous vote of 9 in favor [5].

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 16, 2025, at 14:30 [1] - The meeting will take place at the office building on the first floor, No. 1 Jiekang Road, Industrial Concentration Zone, Zhiqi Town, Jintan District, Changzhou City, Jiangsu Province [1] - Shareholders can vote through the Shanghai Stock Exchange's online voting system from 9:15 to 15:00 on the day of the meeting [1][2] Voting Procedures - The voting will be conducted through a combination of on-site and online voting methods [2] - Shareholders must register to attend the meeting and can authorize a representative to vote on their behalf [4] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [3] Agenda Items - The meeting will review proposals that have been approved by the company's second board of directors [2] - Key proposals include changes to the company's registered capital and the cancellation of the supervisory board [2][8] Attendance Requirements - Shareholders must be registered by the close of trading on September 9, 2025, to attend the meeting [3] - Required documents for registration include proof of shareholding and identification [4] Contact Information - For inquiries, shareholders can contact the Securities Department at 0519-82446601 or via email at lp@chinajek.com [5]

Group 1 - The second meeting of the supervisory board of Jianerkang Medical Technology Co., Ltd. was held on August 28, 2025, with all three supervisors present, complying with relevant laws and regulations [1][2] - The supervisory board approved the 2025 semi-annual report, confirming that the report's preparation and review processes were legal and compliant, and accurately reflected the company's financial status and operational results [1][2] - The supervisory board also approved the special report on the use of raised funds for the first half of 2025, stating that the company adhered to legal procedures and that there were no significant risks associated with the use of these funds [2]

Group 1 - The company has established an Audit Committee under the Board of Directors to enhance decision-making and ensure effective supervision of the management team [1][4] - The Audit Committee consists of three directors, with at least two being independent directors, and is chaired by an independent director with accounting expertise [2][5] - The Audit Committee is responsible for reviewing financial information, supervising internal and external audits, and ensuring the establishment of effective internal controls [4][6] Group 2 - The Audit Committee must have a majority of its members present to exercise its powers, and it is required to hold at least one meeting each quarter [11][23] - The committee is tasked with evaluating the company's internal control systems and must report on its findings alongside the annual financial report [7][9] - The Audit Committee is also responsible for hiring and supervising external auditors, ensuring their independence and adherence to professional standards [10][13] Group 3 - The committee must disclose its annual performance and activities on the Shanghai Stock Exchange website alongside the company's annual report [4][6] - In case of any irregularities, the Audit Committee is obligated to prompt the Board to take necessary actions and disclose relevant information [7][10] - The committee's decisions require a majority vote from all members, and any conflicts of interest must be disclosed and managed appropriately [42][49]

Core Viewpoint - The report indicates a significant decline in the financial performance of Celis Medical Technology Group Co., Ltd. for the first half of 2025, with substantial decreases in revenue and net profit compared to the previous year [1]. Financial Summary - Total assets at the end of the reporting period were approximately ¥2.199 billion, a decrease of 22.30% from the previous year-end [1]. - Operating revenue for the reporting period was approximately ¥583.5 million, reflecting a decline of 40.20% compared to the same period last year [1]. - Total profit for the period was approximately -¥51.93 million, representing a decrease of 495.76% from the previous year [1]. - Net profit attributable to shareholders was approximately -¥56.12 million, with no comparable figure provided for the previous year [1]. - The net cash flow from operating activities was approximately -¥79.17 million, compared to -¥48.88 million in the same period last year [1]. - The weighted average return on net assets decreased by 6.3 percentage points to -6.73% [1]. - Basic and diluted earnings per share were both approximately -¥0.2938, with no prior year comparison available [1]. Shareholder Information - As of the end of the reporting period, the total number of shareholders was 45,698 [2]. - The largest shareholder, Shanghai Saihai Health Technology Co., Ltd., holds 11.33% of shares, amounting to 21,642,540 shares, with 15,800,000 shares pledged [2]. - Other significant shareholders include Shanghai Anze Private Fund Management Co., Ltd. and individual shareholders, with varying percentages and share amounts [2].

Group 1 - The meeting of Cyrus Medical Technology Group Co., Ltd. is scheduled for September 15, 2025, at 14:00 [3][8] - Shareholders must arrive on time and are allowed to participate in voting only if they are present before the voting starts [1][2] - The company will cancel the supervisory board, transferring its responsibilities to the audit committee of the board of directors [6][7] Group 2 - The company plans to change its registered capital from RMB 190,952,305 to RMB 210,139,246 due to the conversion of convertible bonds [7] - The company has issued 5,433,100 convertible bonds with a total amount of RMB 54,331,000, which began conversion on March 1, 2021 [7] - The company will revise its articles of association to comply with updated laws and regulations [9][11] Group 3 - The voting process will be conducted through both on-site and online methods, with specific time slots for voting [5][8] - The meeting will include a series of agenda items, including the reading and deliberation of proposals, shareholder speeches, and voting [8][11] - Legal opinions will be provided by a law firm present at the meeting [3]

Core Points - The implementation rules for cumulative voting at Cyrus Medical Technology Group are established to protect the rights of minority shareholders and ensure compliance with relevant laws and regulations [1][4] - Cumulative voting will be applied when the company elects or replaces directors, particularly when a single shareholder or their concerted parties hold 30% or more of the voting shares and when electing two or more independent directors [1][2] Summary by Sections Cumulative Voting System - The cumulative voting system allows each share to have voting rights equal to the number of directors to be elected, enabling shareholders to concentrate their votes on one candidate or distribute them among several [1][2] - The voting process requires shareholders to indicate their chosen directors and the number of votes allocated to each on a single ballot [2][4] Voting Procedures - If the total votes used by a shareholder exceed their legal voting rights, the ballot will be considered invalid unless corrected [2][4] - The counting of votes will be conducted by the monitoring personnel, and the elected directors must receive more than half of the votes from the attending shareholders [2][4] Information Disclosure - The company is obligated to disclose information regarding the voting system used, the absolute number of votes received by elected directors, and any other relevant matters deemed necessary by the board or independent directors [4] Nomination and Implementation - The nomination procedures for director candidates will follow the company's articles of association [4] - The implementation rules will take effect upon approval by the company's shareholders' meeting and will be interpreted and revised by the board of directors [4]

塞力斯医疗科技集团股份有限公司 信息披露管理制度 塞力斯医疗科技集团股份有限公司 信息披露管理制度 （2025 年 8 月） 第一章 总则 第一条 为了规范塞力斯医疗科技集团股份有限公司（以下简称"公司"） 的信息披露行为，加强信息披露事务管理，保护投资者合法权益，根据《中华人 民共和国公司法》《中华人民共和国证券法》（以下简称"《证券法》"）《上 市公司信息披露管理办法》《上海证券交易所股票上市规则》等法律法规、规章、 规范性文件及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公司章 程》"）的规定，制定本制度。 第二条 信息披露义务人应当及时依法履行信息披露义务，披露的信息应当 真实、准确、完整，简明清晰、通俗易懂，不得有虚假记载、误导性陈述或者重 大遗漏。 信息披露义务人披露的信息应当同时向所有投资者披露，不得提前向任何单 位和个人泄露。但是，法律、行政法规另有规定的除外。 在内幕信息依法披露前，内幕信息的知情人和非法获取内幕信息的人不得公 开或者泄露该信息，不得利用该信息进行内幕交易。任何单位和个人不得非法要 求信息披露义务人提供依法需要披露但尚未披露的信息。 公司证券及其衍生品种同时在境内境外 ...

塞力斯医疗科技集团股份有限公司 重大交易决策制度 塞力斯医疗科技集团股份有限公司 重大交易决策制度 （2025 年 8 月） 第一条 为加强对塞力斯医疗科技集团股份有限公司（以下简称"公司"） 重大交易活动的决策管理，保证重大交易活动的规范性、合法性和效益性，切 实保护公司利益各方的合法权益，根据《中华人民共和国公司法》《中华人民 共和国证券法》《上海证券交易所股票上市规则》等相关法律、法规和《塞力 斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"）的规定， 制定本制度。 第二条 公司应当严格遵守有关法律、法规及《公司章程》的规定，在交 易决策中，保障股东会、董事会和董事长、经理（总裁）各自的权限得到有效 发挥，做到权责分明，保证公司运作效率。 第三条 本制度所称"重大交易"包括除公司日常经营活动之外发生的下 列事项： (一)购买或出售资产； (二)对外投资（含委托理财、对子公司投资等）； (三)提供财务资助（含有息或者无息借款、委托贷款等）； (四)提供担保（含对控股子公司担保等）； (十一)放弃权利（含放弃优先购买权、优先认缴出资权等）； (十二)证券交易所认定的其他交易。 塞力斯医疗科技集团股 ...

塞力斯医疗科技集团股份有限公司 信息披露暂缓与豁免管理制度 第五条 公司和其他信息披露义务人有确实充分的证据证明拟披露的信息 涉及国家秘密或者其他因披露可能导致违反国家保密规定、管理要求的事项（以 下统称"国家秘密"），依法豁免披露。 第六条 公司和其他信息披露义务人有保守国家秘密的义务，不得通过信 息披露、投资者互动问答、新闻发布、接受采访等任何形式泄露国家秘密，不 得以信息涉密为名进行业务宣传。 公司的董事长、董事会秘书应当增强保守国家秘密的法律意识，保证所披露 塞力斯医疗科技集团股份有限公司 信息披露暂缓与豁免管理制度 的信息不违反国家保密规定。 塞力斯医疗科技集团股份有限公司 信息披露暂缓与豁免管理制度 （2025 年 8 月） 第一条 为了规范塞力斯医疗科技集团股份有限公司（以下简称"公司"） 信息披露暂缓与豁免行为，明确公司及相关信息披露义务人依法合规履行信息 披露义务，保护投资者的合法权益，根据《中华人民共和国公司法》《中华人 民共和国证券法》《上市公司信息披露暂缓与豁免管理规定》《上海证券交易 所股票上市规则》等法律法规、规章、规范性文件以及《塞力斯医疗科技集团 股份有限公司章程》（以下简称" ...